MedPath

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Phase 1
Completed
Conditions
Graft vs Host Disease
Registration Number
NCT00032292
Lead Sponsor
Facet Biotech
Brief Summary

The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment. The research is being conducted at up to 10 clinical research sites in the US.

Detailed Description

A Phase I/II, open-label, dose-escalation pilot study designed to obtain preliminary safety, pharmacokinetic (PK) and efficacy information on visilizumab administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). It is anticipated that up to 34 patients at up to 10 study centers could be eligible for enrollment in this study. Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment (2 mg/kg of methylprednisolone IV, or 10 mg/kg hydrocortisone IV, per day). Steroids will be rapidly tapered over one week following visilizumab administration.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (7)

Fred Hutchinson Cancer Research Center

🇺🇸

Seattle, Washington, United States

Duke University

🇺🇸

Durham, North Carolina, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

City of Hope National Medical Center

🇺🇸

Duarte, California, United States

Stanford University Medical Center

🇺🇸

Stanford, California, United States

Washington University School of Medicine

🇺🇸

St. Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath